Melkersson-Rosenthal syndrome (MRS) is characterized by the triad of facial 
paralysis, facial oedema, and lingua plicata in association with other symptoms, 
such as headache and mental changes. Because the origin of this syndrome is 
still unknown, only symptomatic treatment is possible. In 18 patients suffering 
from MRS, whether with a complete or with an incomplete picture, we used the 
antileprosy drug clofazimine for therapy. A decrease in the frequency and 
intensity of oedema was achieved by this therapy in 94% of patients. However, 
improvement persisting throughout a follow-up period of up to 3 years was seen 
in only 62% of patients. We demonstrate that clofazimine is an alternative to 
glucocorticosteroids for the treatment of MRS.